The scale of the undertaking reflects how central robotics has become in Chinese colorectal oncology. Robotic surgery in China is used primarily for rectal cancer, where the anatomy is unforgiving: the pelvis is a bony funnel, tumors sit centimeters from the anal sphincter, and the autonomic nerves controlling urinary and sexual function thread through the dissection plane. A large body of cohort studies and meta-analyses shows that, compared with conventional laparoscopy, robotic rectal cancer surgery improves local tumor radicality, reduces trauma, accelerates recovery, and better preserves those pelvic nerves. Long-term oncological survival appears similar to, and may even exceed, that of laparoscopic surgery. Most strikingly, a multicenter randomized controlled trial found that for mid and low rectal cancer, the robotic approach significantly increased sphincter preservation rates, lowered the rate of positive circumferential resection margins, reduced complications, shortened hospital stays, decreased local recurrence, and improved disease-free survival.

The hardware behind these results is worth understanding in detail. Surgical robotic systems consist of three core components. The surgeon console gives the operating surgeon a high-definition view of the surgical field, with operating handles that simulate multi-degree-of-freedom wrist motion, scale down hand movements by ratios of 1:3 to 1:5, and filter out natural hand tremor through computer processing. The robotic arms, acting as the surgeon’s mechanical hands, carry specialized instruments and energy platforms into the body through converters, with multi-joint or redundant degrees of freedom that allow complex spatial movement and help avoid collisions. An imaging system delivers three-dimensional images magnified ten to fifteen times, providing genuine depth perception. Some advanced platforms integrate ultrasound and fluorescence imaging, support augmented reality with haptic feedback, and even use blockchain-encrypted data transmission as infrastructure for telesurgery. With artificial intelligence, 5G connectivity, and new energy platforms converging on the operating room, the consensus authors expect future systems to become more intelligent, more holographic, and more cloud-based.

One of the document’s most practical contributions is its treatment of the learning curve. Robotic surgery turns out to be easier to learn than laparoscopy: studies cited in the consensus indicate that approximately 25 to 44 colorectal cases are needed to master the core techniques and reach the first plateau of proficiency, an advantage over the laparoscopic route. Prior laparoscopic experience helps shorten the training period but is not essential. Before operating, a chief surgeon must complete basic robotic training, obtain the relevant qualification certificate, and undergo procedure-specific training. The consensus also elevates roles often overlooked in surgical narratives. Assistants are deemed as important as the lead surgeon and should have laparoscopic experience plus 30 supervised robotic cases. Scrub nurses require comprehensive training in instrument selection, protective sleeve installation, system positioning, and simple fault identification, because a stalled robotic arm in the middle of a pelvic dissection is not a problem anyone wants to improvise around.

Beyond standard resections, the consensus dives deep into two frontier techniques that are redefining what minimally invasive surgery means. The first is natural orifice specimen extraction surgery, or NOSES, in which the resected tumor is removed through the rectum or vagina rather than through an auxiliary abdominal incision, moving the field closer to genuinely scarless surgery. Growing evidence suggests the oncological outcomes of NOSES are non-inferior to conventional laparoscopic surgery, though most studies remain single-center and retrospective, and the authors call for large multicenter prospective trials and randomized studies to establish long-term safety definitively. The second is transanal total mesorectal excision, or TaTME, a bottom-up approach particularly useful for obese patients, male patients, and those with narrow pelvises. A randomized clinical trial demonstrated that the three-year disease-free survival rate after TaTME is not inferior to laparoscopic TME, with no significant differences in overall survival or local recurrence. Preliminary findings from the prospective RESET trial, which compared open, laparoscopic, robotic-assisted, and TaTME approaches in high-risk rectal cancer patients, showed a consistent R0 resection rate of 96 percent across all techniques, with no statistically significant differences in primary outcomes.

The consensus is equally candid about when robots should not be used, and when they should be abandoned mid-operation. Absolute contraindications include severe cardiopulmonary disease that precludes anesthesia and extensive distant metastases where radical cure is impossible. Relative contraindications include coagulation abnormalities and extensive intra-abdominal adhesions. Conversion to open surgery becomes necessary for advanced tumors invading vital organs, large-volume tumors, anatomy that prevents safe robotic dissection, uncontrollable major bleeding, and equipment failure that cannot be quickly resolved. The authors urge surgeons to assess conversion risk preoperatively and to act decisively when indications appear, noting that in emergencies, the robotic arms can simply be withdrawn from the open surgical field rather than fully undocking the system.

Perhaps the most strategically significant section concerns the competitive landscape of robotic platforms. The da Vinci system of Intuitive Surgical still holds the largest global market share, now updated to the da Vinci 5 with more powerful computing, improved precision, and force-sensing technology. Medtronic’s Hugo RAS system offers a modular, open design with cost advantages, while CMR Surgical’s Versius provides a smaller, flexible modular alternative, and Johnson & Johnson’s integrated Ottava has received FDA investigational device exemption approval. Meanwhile, domestic Chinese robots have advanced rapidly: multi-arm systems from Medbot, Jingfeng, Wego, Kangduo, and Cornerstone have reached clinical application, and single-port systems from Shurui and Jingfeng have received domestic marketing approval and achieved global first-in-human surgeries across multiple specialties. The consensus notes that Chinese robots are closing the technological gap, substituting for imports, and taking a global lead in integrating AI into surgical planning and implementing 5G remote surgery, with platform and consumable cost advantages poised to expand clinical adoption quickly.

Technically, the document reads almost like an operations manual, specifying everything from trocar spacing to instrument configurations. For a robotic-assisted right hemicolectomy using the da Vinci Xi, five trocars are placed with the camera port 3 to 4 centimeters left-inferior to the umbilicus and operative ports spaced 8 to 10 centimeters apart to prevent arm collision, with pneumoperitoneum maintained at 8 to 15 mmHg. The consensus codifies the oncological principles that no platform can bypass: complete mesocolic excision for colon cancer, with sharp dissection along embryological planes and high ligation of vascular roots; total mesorectal excision for rectal cancer, requiring distal bowel margins of at least 2 centimeters and distal mesorectal resection of at least 5 centimeters; and root lymph node dissection extending to the origins of the feeding arteries. It also endorses preoperative adjuncts such as indocyanine green fluorescence imaging for real-time visualization of lymphatic drainage and anastomotic blood supply, and carbon nanoparticle tracing injected under colonoscopic guidance two hours before surgery to stain lymph nodes for dissection guidance.

The consensus extends robotic surgery into territory once considered the exclusive domain of open surgery, including combined resections of the liver, pancreas, spleen, uterus, bladder, seminal vesicles, and prostate when colorectal cancer invades adjacent organs. It provides detailed guidance for operating after neoadjuvant chemoradiotherapy, recommending an interval of 4 to 8 weeks or longer and exploiting the robot’s stability and three-dimensional vision to dissect through edematous, fibrotic tissue in the narrow pelvic floor. Complication management receives its own thorough treatment, covering anastomotic leaks, bowel obstruction, urinary and sexual dysfunction, chyle leaks, and uniquely robotic hazards such as instruments trapping tissue at their joints, ruptured protective sleeves causing accidental burns, and total system failure requiring conversion. Single-port robotic surgery, which solves the instrument-collision problems of single-port laparoscopy, is described as promising but early-stage, with suggested indications limited to tumors of 4 centimeters or less in patients with a body mass index below 28.

What emerges from nearly one hundred and fifty pages of technical detail is a portrait of a surgical discipline in transition. Robotic rectal cancer surgery has crossed from novelty to evidence-backed standard, with randomized trials supporting better sphincter preservation, fewer positive margins, and improved disease-free survival in mid and low rectal tumors, while cost-effectiveness data, though still sparse, suggest higher total costs may be offset by greater quality-adjusted life years. Colon cancer robotics lags behind, since the larger operative space and need to transition between multiple surgical fields diminish the robot’s advantages in a domain where laparoscopy is already well established. The 2025 consensus, produced through nationwide expert discussion with support from a major national science and technology project, is designed to standardize training, indications, technique, and failure management so that the technology’s promise reaches patients consistently. For the growing number of surgeons watching robotic arms suture inside a bony pelvis in high-definition 3D, the message is clear: the future of colorectal cancer surgery is increasingly mechanical, increasingly precise, and increasingly homegrown.

Subject of Research: Robotic surgery techniques and clinical standards for colorectal cancer treatment in China

Article Title: Chinese expert consensus on robotic surgery for colorectal cancer (2025 edition)

Article References: Wang, X., Xu, J., Zhou, Y., Yao, H., Xiong, D., She, J., on behalf of Robotic Surgery Group, Colorectal Cancer Committee of Chinese Medical Doctor Association, Bai, W., Cai, G., Chen, C., Chen, G., Chen, H., Chen, Z., Cheng, L., Cheng, Y., Chi, P., Chi, Z., Cui, B., Dang, C., … Zhou, H. (2026). Chinese expert consensus on robotic surgery for colorectal cancer (2025 edition). Clinical Cancer Bulletin, 5(1), Article 2. https://doi.org/10.1007/s44272-026-00054-6

Image Credits: AI Generated

DOI: 10.1007/s44272-026-00054-6

Keywords: robotic surgery, colorectal cancer, rectal cancer, total mesorectal excision, NOSES, TaTME, da Vinci system, minimally invasive surgery, surgical robotics, lymph node dissection, Chinese expert consensus, surgical training

As prostate cancer predominantly affects middle-aged and elderly men, the lack of unified clinical guidelines poses significant challenges in patient care. The complexity of the disease, especially when distinguishing between localized and metastatic cases, exacerbates the urgency for informed and standardized management practices. Despite various international and domestic guidelines existing, there remains a daunting void in high-level evidence concerning crucial aspects of prostate cancer treatment. This inadequacy has led Chinese experts to unite in a concerted effort to enhance the standard of care, making timely interventions possible to improve health outcomes for patients afflicted by this disease.

The consensus, which was published on October 10, 2024, in the prestigious journal UroPrecision, reflects extensive deliberations and collective input from a panel of elite specialists, including urologists, medical oncologists, and radiologists. These experts addressed 19 pivotal questions focusing on various aspects of prostate cancer management, ranging from screening protocols and biopsy techniques to advanced treatment options for localized, locally advanced, and metastatic disease. The thorough examination of these topics demonstrates the commitment of Chinese professionals to establish a well-defined framework that clinicians can follow to navigate the complexities of prostate cancer effectively.

One of the most significant conclusions drawn from the consensus is the overwhelming support for prostate-specific antigen (PSA) screening, with a noteworthy 89% of the participating experts affirming its efficacy in reducing prostate cancer-specific mortality rates. This statistic serves as a powerful testament to the importance of early detection in combating the disease. The experts recommend initiating PSA screening at the age of 50 for men who do not have a family history of prostate cancer or carry BRCA2 mutations, thereby setting a clear benchmark for preventive healthcare practices.

In the realm of treatment strategies, the consensus advocates for the incorporation of next-generation hormonal agents in combination with androgen deprivation therapy (ADT) for patients diagnosed with high-volume metastatic castration-sensitive prostate cancer. This progressive approach emphasizes the need for advanced treatment modalities that can tackle the aggressive nature of metastatic forms of the disease. For individuals categorized as nonmetastatic castration-resistant prostate cancer patients, about 75% of experts concurred that additional assessments, such as Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography/Computed Tomography (PET/CT), should be pursued in cases where standard imaging fails to reveal metastasis.

This consensus reflects a significant stride toward the standardization of prostate cancer management in China, as articulated by Nianzeng Xing, the corresponding author of the study. He highlighted that this document serves as a vital reference that offers comprehensive guidance for clinicians, documenting the entire patient journey from screening to final treatment and follow-up. Such a meticulous effort underlines how experts aim to transform the management landscape of prostate cancer, providing a lifeline for patients who are grappling with the complexities of their treatment options.

Furthermore, the consensus document sets forth actionable, evidence-based recommendations engineered to support healthcare professionals in effectively navigating the challenging terrain of prostate cancer management. By highlighting critical challenges and offering a cohesive resolution through expert-driven consensus, there lies potential not only to elevate patient outcomes but also to enhance the quality of life for those battling the disease. These strategic recommendations related to both screening practices and treatment protocols stand poised to make a substantial difference in the clinical practices deployed throughout China.

The rapidly increasing incidence of prostate cancer necessitates a proactive and unified response from the medical community. The consensus created by noted specialists could serve as a vital instrument in fighting against this growing health threat, paving the way for improved care and treatment methodologies that could ultimately reduce the burden of the disease. The forward-thinking initiatives encapsulated in the consensus aim to foster a more structured approach to managing prostate cancer, all while paying careful attention to the nuances of patient care.

As the healthcare system continues to evolve, the implications of this consensus could resonate far beyond just clinical settings. By addressing pressing medical challenges through expert-driven insights, the guidelines foster a culture of collaboration and standardization that could enhance overall health outcomes for patients across China, regardless of geographic or socioeconomic barriers. The collective effort in forging this consensus illustrates a powerful commitment to advancing care standards while ensuring that healthcare professionals are equipped with the knowledge necessary to confront prostate cancer effectively.

In summation, the consensus published in UroPrecision marks a crucial advance in the discourse surrounding prostate cancer management in China. The syntheses of expert opinions and the establishment of a coherent framework signify a turning point in how clinicians will approach diagnosis, treatment, and patient follow-up strategies. The diligence shown by Chinese specialists in crafting this document embodies a proactive commitment to improving patient care and addressing the immediate needs of those affected by prostate cancer, presenting a large step forward in the quest for improved survival rates and health outcomes in the face of an escalating health challenge.

Subject of Research: Prostate Cancer Management
Article Title: Hot Issues on Chinese Expert Consensus of Prostate Cancer Management
News Publication Date: 10-Oct-2024
Web References: UroPrecision
References: DOI 10.1002/uro2.76
Image Credits: Not applicable

Keywords: Prostate cancer, PSA screening, androgen deprivation therapy, metastatic prostate cancer, clinical guidelines.